Apollo Endosurgery, Inc. (APEN): Price and Financial Metrics
APEN Price/Volume Stats
|Current price||$10.00||52-week high||$10.30|
|Prev. close||$9.92||52-week low||$3.49|
|Day high||$10.00||Avg. volume||1,432,125|
|50-day MA||$9.91||Dividend yield||N/A|
|200-day MA||$7.43||Market Cap||579.72M|
APEN Stock Price Chart Interactive Chart >
Apollo Endosurgery, Inc. (APEN) Company Bio
Apollo Endosurgery, Inc. focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company is based in Austin, Texas.
APEN Latest News Stream
|Loading, please wait...|
APEN Latest Social Stream
View Full APEN Social Stream
Latest APEN News From Around the Web
Below are the latest news stories about APOLLO ENDOSURGERY INC that investors may wish to consider to help them evaluate APEN as an investment opportunity.
Apollo Endosurgery ( NASDAQ:APEN ) Full Year 2022 Results Key Financial Results Revenue: US$76.9m (up 22% from FY...
Key Insights Apollo Endosurgery's estimated fair value is US$7.40 based on 2 Stage Free Cash Flow to Equity Apollo...
In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts Are Downgrading These 5 Stocks. Microsoft Corporation (NASDAQ:MSFT) is in the news after the company posted fiscal Q2 results. The company’s revenue outlook for the March […]
Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity
Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices
Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.
APEN Price Returns
Continue Researching APENWant to see what other sources are saying about Apollo Endosurgery Inc's financials and stock price? Try the links below:
Apollo Endosurgery Inc (APEN) Stock Price | Nasdaq
Apollo Endosurgery Inc (APEN) Stock Quote, History and News - Yahoo Finance
Apollo Endosurgery Inc (APEN) Stock Price and Basic Information | MarketWatch